Genetic Variants of Pregnane X Receptor (PXR) and CYP2B6 Affect the Induction of Bupropion Hydroxylation by Sodium Ferulate

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Gao, Lichen ^a,b   He, Yijing ^a,c   Tang, Jie ^a   Yin, Jiye ^a   Huang, Zhengyu ^b   Liu, Fangqun ^b   Ouyang, Dongsheng ^a   Chen, Xiaoping ^a   Zhang, Wei ^a   Liu, Zhaoqian ^a   Zhou, Honghao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGSHA CENTRAL HOSPITAL   (China)

^c University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2B6; FERULIC ACID; PREGNANE X RECEPTOR; COUMARIC ACID; CYP2B6 PROTEIN, HUMAN; RADAFAXINE; STEROID RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CYTOCHROME P450 2B6 GENE; DOSE RESPONSE; DRUG HYDROXYLATION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOTE DETECTION; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PREGNANE X RECEPTOR GENE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; ANALOGS AND DERIVATIVES; CROSSOVER PROCEDURE; DRUG EFFECTS; DRUG INTERACTION; GENETIC VARIATION; GENETICS; GENOTYPE; HYDROXYLATION; METABOLISM; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; BUPROPION; COUMARIC ACIDS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2B6; DRUG INTERACTIONS; GENETIC VARIATION; GENOTYPE; HUMANS; HYDROXYLATION; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; YOUNG ADULT;

EID: 84879218548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062489     Document Type: Article

References (59)

1. Bailey I, Gibson GG, Plant K, Graham M, Plant N, (2011) A PXR-mediated negative feedback loop attenuates the expression of CYP3A in response to the PXR agonist pregnenalone-16alpha-carbonitrile. PLoS One 6: e16703.
2. Saradhi M, Krishna B, Mukhopadhyay G, Tyagi RK, (2005) Purification of full-length human pregnane and Xenobiotic receptor: polyclonal antibody preparation for immunological characterization. Cell Research 15: 785-795.
3. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82.
4. Blumberg B, Sabbagh WJ, Juguilon H, Bolado JJ, van Meter CM, et al. (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12: 3195-3205.
5. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, et al. (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95: 12208-12213.
6. Jones SA, Moore LB, Shenk JL, Wisely GB, Hamilton GA, et al. (2000) The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 14: 27-39.
7. Yueh MF, Kawahara M, Raucy J, (2005) High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 33: 38-48.
8. Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, et al. (2001) Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 268: 6346-6358.
9. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB, (2003) Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73: 41-50.
10. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, et al. (2000) St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97: 7500-7502.
11. Lau AJ, Yang G, Rajaraman G, Baucom CC, Chang TK, (2010) Human pregnane X receptor agonism by Ginkgo biloba extract: assessment of the role of individual ginkgolides. J Pharmacol Exp Ther 335: 771-780.
12. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, et al. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102: 1016-1023.
13. Wang HB, Faucette S, Sueyoshi T, Moore R, Ferguson S, et al. (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278: 14146-14152.
14. Frank C, Makkonen H, Dunlop TW, Matilainen M, Väisänen S, et al. (2005) Identification of pregnane X receptor binding sites in the regulatory regions of genes involved in bile acid homeostasis. J Mol Biol 346: 505-519.
15. Olinga P, Elferink MG, Draaisma AL, Merema MT, Castell JV, et al. (2008) Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 33: 380-389.
16. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29: 1454-1459.
17. Wang XD, Li JL, Su QB, Guan S, Chen J, et al. (2009) Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol 67: 255-261.
18. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, et al. (2001) The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11: 555-572.
19. Uno Y, Sakamoto Y, Yoshida K, Hasegawa T, Hasegawa Y, et al. (2003) Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 48: 594-597.
20. Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, et al. (2011) Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos 39: 92-97.
21. Chen LL, Qi J, Chang YX, Zhu DN, Yu BY, (2009) Identification and determination of the major constituents in Traditional Chinese Medicinal formula Danggui-Shaoyao-San by HPLC-DAD-ESI-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 50: 127-137.
22. Zhang YJ, Huang X, Wang Y, Xie Y, Qiu XJ, et al. (2011) Ferulic acid-induced anti-depression and prokinetics similar to Chaihu-Shugan-San via polypharmacology. Brain Res Bull 86: 222-228.
23. Wang BH, Ouyang JP, Liu YM, Yang JW, Wei L, et al. (2004) Sodium ferulate inhibits atherosclerogenesis in hyperlipidemia rabbits. J Cardiovasc Pharmacol 43: 549-554.
24. Traore M, Hong JL, Xu CL, (2003) Influence of Angelicae sinensis extract on lipid accumulation in rabbit aortic smooth muscle cells induced by oxidized LDL. Biorheology 40: 389-394.
25. Barone E, Calabrese V, Mancuso C, (2009) Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology 10: 97-108.
26. Liu HQ, Sun Y, Gao Y, Chen FF, Xu MB, et al. (2010) The analgesic effect and mechanism of the combination of sodium ferulate and oxymatrine. Neurochem Res 35: 1368-1375.
27. Srinivasan M, Sudheer AR, Menon VP, (2007) Ferulic Acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr 40: 92-100.
28. Wang BH, Ou-Yang JP, (2005) Pharmacological actions of sodium ferulate in cardiovascular system. Cardiovasc Drug Rev 23: 161-172.
29. Wang HB, Tompkins LM, (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9: 598-610.
30. Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, et al. (2000) Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 28: 1222-1230.
31. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, et al. (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28: 1176-1183.
32. Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, et al. (2009) Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol 65: 403-409.
33. Hogeland GW, Swindells S, McNabb JC, Kashuba ADM, Yee GC, et al. (2007) Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects. Clin Pharmacol Ther 81: 69-75.
34. Gao LC, Huang X, Tan ZR, Fan L, Zhou HH, (2012) The effects of sodium ferulate on the pharmacokinetics of bupropion and its active metabolite in healthy men. European Review for Medical and Pharmacological Sciences (in press).
35. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, et al. (2011) Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J Pharmacol Exp Ther 338: 803-809.
36. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, et al. (2007) CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 21: 2191-2199.
37. Nyakutira C, Röshammar D, Chigutsa E, Chonzi P, Ashton M, et al. (2008) High prevalence of the CYP2B6 516G>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. Eur J Clin Pharmacol 64: 357-365.
38. Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, et al. (2007) CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol Psychiatry 62: 635-641.
39. Chen J, Jiang WM, Gao XL, Jiang X, Zhang QZ, et al. (2004) Bioequivalence evaluation of two rabeprazole enteric coated formulations in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet 29: 103-106.
40. ICH Guideline for Good Clinical Practice CPMP/ICH/135/95. Available: http://www.emea.europa.eu/pdfs/human/ich/013595en.pdf. Accessed 25 May 2012.
41. Moreira RPP, Jorge AAL, Mendonca BB, Bachega TASS, (2011) Frequency of genetic polymorphisms of PXR gene in the Brazilian population. Clinics (Sao Paulo) 66: 1041-1044.
42. Sandanaraj E, Lal S, Selvarajan V, Ooi LL, Wong ZW, et al. (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14: 7116-7126.
43. Wang XD, Li JL, Su QB, Deng XY, Lu Y, et al. (2007) A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Curr Drug Metab 8: 778-786.
44. Lin YS, Yasuda K, Assem M, Cline C, Barber J, et al. (2009) The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos 37: 1295-1304.
45. Lim YP, Huang JD, (2008) Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 23: 14-21.
46. Ourlin JC, Lasserre F, Pineau T, Fabre JM, Sa-Cunha A, et al. (2003) The small heterodimer partner interacts with the pregnane X receptor and represses its transcriptional activity. Mol Endocrinol 17: 1693-1703.
47. Li TG, Chiang JYL, (2003) Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4αand coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34: 756-764.
48. Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, et al. (2011) Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. J Antimicrob Chemother 6: 1-7.
49. Lamba J, Lamba V, Schuetz E, (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6: 369-383.
50. Svärd J, Spiers JP, Mulcahy F, Hennessy M, (2010) Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. J Acquir Immune Defic Syndr 55: 536-549.
51. Duniec-Dmuchowski Z, Ellis E, Strom SC, Kocarek TA, (2007) Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists. Biochem Pharmacol 74: 1535-1540.
52. Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ, (2002) Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem 277: 25125-25132.
53. Wang H, Faucette SR, Gilbert D, Jolley SL, Sueyoshi T, et al. (2003) Glucocorticoid receptor enhancement of pregnane X receptor mediated CYP2B6 regulation in primary human hepatocytes. Drug Metab Dispos 31: 620-630.
54. Mukonzo JK, Röshammar D, Waako P, Andersson M, Fukasawa T, et al. (2009) A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. Br J Clin Pharmacol 68: 690-699.
55. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, et al. (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307: 906-922.
56. King CR, Xiao M, Yu J, Minton MR, Addleman NJ, et al. (2007) Identification of NR1I2 genetic variation using resequencing. Eur J Clin Pharmacol 63: 547-554.
57. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E, (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36: 169-181.
58. Folwaczny M, Tengler B, Glas J, (2012) Variants of the human NR1I2 (PXR) locus in chronic periodontitis. J Periodontal Res 47: 174-179.
59. Ni WJ, Ji J, Dai ZY, Papp A, Johnson AJ, et al. (2010) Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5: e13792.